Abilita Bio is a biotechnology company focused on developing technologies to enable discovery and development of drugs targeting challenging membrane proteins, including GPCRs and ion channels.

Ion channel targets: Nav1.7, Nav1.8
Indication: Pain
Website: http://www.abilitabio.com/
Location: San Diego, USA

Acadia Pharmaceuticals is a biopharmaceutical company developing innovative medicines to address unmet medical needs in central nervous system disorders.

Ion channel targets: TRPA1
Indication: Postoperative pain, Pain associated with osteoarthritis
Website: https://www.acadia-pharm.com/
Location: San Diego, USA

A Danish biotech company developing more efficacious and safer drugs for the treatment of atrial fibrillation.

Ion channel targets: SK
Indication: Atrial fibrillation
Website: http://www.acesionpharma.com
Location: København, Denmark

Aerie Pharmaceuticals discover, develop, and commercialize first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases.

Ion channel targets: TRPM8
Indication: Dry eye disease
Website: https://aeriepharma.com/
Location: Durham, USA

Algiax Pharmaceuticals is a clinical-stage biotechnology company focused on development of GABAA receptor modulators for neuropathic pain and other indications with unmet medical need.

Ion channel targets: GABAA
Indication: Neuropathic pain, Diabetes
Website: http://www.algiax.com/
Location: Erkrath, Germany

Alion Pharmaceuticals develops a pipeline of small molecule therapeutics for the treatment of Alzheimer’s disease and other CNS diseases.

Ion channel targets: 0
Indication: Alzheimer’s disease
Website: https://www.alion-pharmaceuticals.com
Location: Menlo Park, USA

AlzeCure® is a Swedish pharmaceutical company that develops new innovative drug therapies for the treatment of severe diseases and conditions that affect the central nervous system, such as Alzheimer’s disease and pain.

Ion channel targets: TRPV1
Indication: Alzheimer’s disease, pain
Website: https://www.alzecurepharma.se/en/
Location: Huddinge, Sweden

Amgen is a multinational biopharmaceutical company discovering, developing, manufacturing and delivering innovative human therapeutics.

Ion channel targets: Nav 1.7
Indication: Multiple
Website: https://www.amgen.com/
Location: Thousand Oaks, USA

Arcturus Therapeutics is a clinical-stage messenger RNA medicines company focused on the discovery, development and commercialization of therapeutics for rare diseases and vaccines.

Ion channel targets: CFTR
Indication: Cystic fibrosis
Website: https://arcturusrx.com/
Location: San Diego, USA

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Ion channel targets: ENaC
Indication: Cystic fibrosis
Website: https://arrowheadpharma.com/
Location: Pasadena, USA

Asana BioSciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel targeted therapies in inflammation/immunology and oncology.

Ion channel targets: Sodium channels, P2X3
Indication: Pruritus, Atopic dermatitis, Cough, Pain
Website: https://www.asanabiosciences.com/
Location: Lawrenceville, USA

Autifony Therapeutics is a UK-based company dedicated to developing new drugs to treat rare CNS disorders. Modulators of Kv3.1 and Kv3.2 channels to treat disorders of the central nervous system.

Ion channel targets: Kv3.1/Kv3.2, lysosomal ion channel, Novel Genetically linked Ion Channel
Indication: Fragile X, Progressive Myoclonic Epilepsy, Amyotrophic Lateral Sclerosis, Schizophrenia, Bipolar Disorder
Website: https://autifony.com
Location: Hertfordshire, United Kingdom

Axsome Therapeutics is a biopharmaceutical company developing novel therapies for CNS conditions that have limited treatment options.

Ion channel targets: NMDA receptor
Indication: Major depressive disorder, Alzheimer’s disease agitation, Smoking cessation
Website: https://www.axsome.com/
Location: New York, USA

BELLUS Health is a clinical stage biotechnology company developing novel therapeutics for the treatment of chronic cough and other chronic disorders triggered by hypersensitization.

Ion channel targets: P2X3
Indication: Chronic cough, chronic pruritus
Website: https://bellushealth.com/
Location: Laval, Canada

Biogen is a multinational biotechnology company focused on discovery, development and delivery of innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Development of Nav1.7 blockers for the treatment of neuropathic pain (BIIB074 -vixotrigine and BIIB095).

Ion channel targets: Nav 1.7
Indication: Trigeminal neuralgia, Small fiber neuropathy, Neuropathic pain
Website: https://www.biogen.com
Location: Cambridge, USA

Bionomics is a global, clinical-stage biopharmaceutical company developing novel ion channel modulators for patients with underserved CNS disorders.

Ion channel targets: nAChRa7, Nav 1.7/Nav1.8, Kv3.1/Kv3.2
Indication: Post-Traumatic Stress Disorder, Social Anxiety Disorder, Alzheimer’s disease, Chronic Pain, cognitive deficits, schizophrenia and autism spectrum disorders.
Website: https://www.bionomics.com.au
Location: Eastwood, Australia

Biosceptre is a biopharmaceutical company developing targeted therapeutics and immune-oncology products for cancer patients.

Ion channel targets: nfP2X7
Indication: Liquid and solid tumours
Website: http://www.biosceptre.com/
Location: Cambridge, United Kingdom

CalciMedica is a clinical stage biopharmaceutical company developing inhibitors of CRAC channels for the treatment of inflammatory diseases, including acute pancreatitis and COVID-19 pneumonia.

Ion channel targets: CRAC
Indication: Acute pancreatitis, COVID-19 pneumonia, Acute respiratory distress syndrome, Acute flu pneumonia, acute lung injury, acute kidney injury
Website: https://calcimedica.com/
Location: La Jolla, USA

Caraway Therapeutics is a biopharmaceutical company developing small-molecule therapeutics for the treatment of neurodegenerative and rare diseases.

Ion channel targets: TRPML1, TMEM175
Indication: Parkinson’s disease, Amyotrophic Lateral Sclerosis, lysosomal storage diseases
Website: https://carawaytx.com/
Location: Cambridge, USA

Casma Therapeutics is a biotechnology company harnessing autophagy and the lysosome to design new medicines for a broad range of diseases.

Ion channel targets: TRPML1
Indication: 0
Website: https://www.casmatx.com/
Location: Cambridge, USA

Cavion is a clinical-stage pharmaceutical company developing first-in-class therapies to restore the brain’s natural rhythms by modulating overactive T-type calcium channels for a range of neurological and rare genetic diseases. Cavion is now a wholly-owned subsidiary of Jazz Pharmaceuticals.

Ion channel targets: Cav3.x
Indication: Essential tremmor
Website: http://cavionpharma.com/
Location: Dublin, Ireland

Celex Oncology is focused on discovery of voltage-gated sodium channel modulators for treating aggressive, invasive and metastatic cancer forms.

Ion channel targets: Nav
Indication: Aggressive, invasive and metastatic tumours
Website: http://celex-oncology.com
Location: Liverpool, UK

Cerevel Therapeutics is a clinical-stage biopharmaceutical company discovering and developing new therapies for people suffering from neuroscience diseases, including Parkinson’s disease, epilepsy and schizophrenia. Development of CVL-865, a novel α2/3/5-subtype selective GABAA receptor positive allosteric modulator, for the treatment of epilepsy.

Ion channel targets: GABAA
Indication: Epilepsy, Anxiety
Website: https://www.cerevel.com/
Location: Cambridge, USA

CODA Biotherapeutics imploys gene therapy approach to express tunable ligand-gated ion channels in neurons for the treatment of neurological diseases,

Ion channel targets: Engineered ligand-gated ion channels
Indication: Neuropathic pain, focal epilepsy
Website: https://www.codabiotherapeutics.com/
Location: San Francisco, USA

CyThera Pharmaceuticals accelerates the development of autoimmune therapeutics by repurposing existing FDA-approved drugs for new disease indications in cancer, stroke and immune disease.

Ion channel targets: Kv1.3
Indication: Psoriatic skin lesions, multiple sclerosis, rheumatoid arthritis.
Website: https://www.cytherapharm.com/
Location: Honolulu, USA

Daewoong Pharmaceuticals is a public South Korean pharmaceutical company that develops, manufactures, and commercializes pharmaceuticals.

Ion channel targets: Nav1.7
Indication: Chronic pain
Website: https://www.daewoong.com/en/main/index
Location: Seoul, South Korea

Encoded Therapeutics develops novel approach to gene therapy for people living with pediatric CNS diseases.

Ion channel targets: Nav1.1
Indication: Dravet syndrome
Website: https://encoded.com/
Location: San Francisco, USA

Engrail Therapeutics is a neuroscience company focused on the acquisition, development and commercialization of patient-centric therapies.

Ion channel targets: GABAA
Indication: Diseases of the nervous system
Website: https://engrail.com/
Location: San Diego, USA

Enterprise Therapeutics is a drug discovery company dedicated to the research and development of novel therapies for the treatment of respiratory diseases.

Ion channel targets: ENaC, TMEM16A
Indication: Cystic fibrosis, Asthma, Chronic obstructive pulmonary disease
Website: http://enterprisetherapeutics.com
Location: Brighton, United Kingdom

Flexion Therapeutics is a biopharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), post-operative pain and low back pain.

Ion channel targets: Nav1.7
Indication: Postoperative pain
Website: https://flexiontherapeutics.com/
Location: Burlington, USA

Glenmark Pharmaceuticals is a pharmaceutical company dedicated to address unmet medical needs in inflammation disorders, especially in respiratory and dermatology therapies and also oncology.

Ion channel targets: TRPA1
Indication: Neuropathic pain
Website: http://www.glenmarkpharma.com
Location: Mumbai, India

Goldfinch Bio is developing precision medicine product candidates for patients with kidney diseases.

Ion channel targets: TRPC5
Indication: Focal Segmental Glomeruloscleosis
Website: https://www.goldfinchbio.com/
Location: Cambridge, USA

HD Biosciences, a WuXi AppTec company, is a Shanghai based company, specializing in high value drug discovery contract research services.

Ion channel targets: 0
Indication: 0
Website: https://www.hdbiosciences.com/
Location: Shanghai, China

Integral Molecular is a research-driven biotechnology company creating innovative technologies and a pipeline of therapeutic antibodies for under-exploited membrane protein targets, including GPCRs, ion channels, and transporters.

Ion channel targets: P2X7, P2X3, Kv1.3, Nav1.7
Indication: 0
Website: https://www.integralmolecular.com/
Location: Philadelphia, USA

Kineta is a clinical stage biotechnology company with a mission to develop next generation immunotherapies.

Ion channel targets: alpha9alpha10 nAChR
Indication: Neuropathic pain
Website: https://www.kinetabio.com
Location: Seattle, USA

Knopp Biosciences is a drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases. Development of Kv7 modulators for the treatmnet of epileptic encelophaty, neuropathic pain, hearing disorders and ALS

Ion channel targets: Kv7
Indication: KCNQ2 epileptic encephalopathy, neuropathic pain, hearing disorders, Amyotrophic lateral sclerosis
Website: https://knoppbio.com/
Location: Pittsburgh, USA

Lilly is a biopharmaceutical company discovering, developing and manufacturing pharmaceutical products.

Ion channel targets: P2X7, TRPA1
Indication: Chronic pain
Website: https://www.lilly.com
Location: Indianapolis, USA

Maxion uses its innovative KnotBody technology in combination with in vitro display technologies to generate therapeutic candidates against ion channels and GPCR proteins.

Ion channel targets: 0
Indication: 0
Website: https://maxion.co.uk/
Location: Cambridge, UK

Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders.

Ion channel targets: Cav3.x, Nav1.6, AMPA
Indication: Epileptic Encephalopathy, Essential tremor, adult focal epilepsy, rare pediatric epilepsy, major depressive disorder
Website: https://www.neurocrine.com/
Location: San Diego, USA

Neuroservice is a contract research organization providing pharmacological assays based on electrophysiological recordings of acute brain slices, spinal cord slices, cultured neurons, human brain slices and iPSC-derived neurons.

Ion channel targets: 0
Indication: 0
Website: http://www.neuroservice.com/
Location: Le Puy-Sainte-Réparade, France

NMD Pharma discovers and develops novel therapeutics for neuromuscular diseases.

Ion channel targets: CLC1
Indication: Myasthenia Gravis
Website: https://www.nmdpharma.com/
Location: Aarhus, Denmark

NOCION is a biopharmaceutical company developing “nocions”—a new kind of therapy that selectively affects actively firing nociceptors—to provide targeted, robust and sustained relief for the treatment of serious conditions including cough, itch, pain and inflammation.

Ion channel targets: Nav
Indication: Chronic cough, chronic pruritus
Website: https://www.nociontx.com
Location: Waltham, USA

Novassay is a biotechnology company pursuing drug development programs in neuropathic pain and oncology.

Ion channel targets: CACNA2D1, hERG, Nav1.7
Indication: Neuropathic pain
Website: http://www.novassay.com
Location: Epalinges, Switzerland

ONO is an R&D-oriented pharmaceutical company developing and manufacturing pharmaceutical products.

Ion channel targets: HCN
Indication: Chronic heart failure
Website: https://www.ono-pharma.com/
Location: Osaka, Japan

Parion Sciences is a development stage company dedicated to research, development, and commercialization of therapies to restore the innate mucosal surface defense of the lung. ENaC inhibitors for the treatment of pulmonary diseases (in partnership with Vertex) and dry eye disease. Small molecule CFTR correctors for the treatment of cystic fibrosis.

Ion channel targets: ENaC
Indication: Cystic fibrosis, chronic obstructive pulmonary disease, primary ciliary dyskinesia, asthma
Website: http://www.parion.com
Location: Durham, USA

PILA PHARMA is a clinical stage pharmaceutical company developing a TRPV1 antagonist, XEN-D0501, for the treatment of diabetes.

Ion channel targets: TRPV1
Indication: Type 2 diabetes
Website: http://pilapharma.com/
Location: Malmö, Sweden

Praxis is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for patients affected by CNS disorders characterized by neuronal imbalance.

Ion channel targets: GABAA, CACNA1G, SCN8A, KCNT1, SCN2A,
Indication: Pediatric epilepsies, depression, pain syndrome
Website: https://praxismedicines.com/
Location: Boston, USA

QurAlis is a biotech company focused on developing precision medicines for amyotrophic lateral sclerosis (ALS) and other neurologic diseases.

Ion channel targets: Kv7.2/7.3
Indication: Amyotrophic lateral sclerosis
Website: https://quralis.com/
Location: Cambridge, USA

Redpin Therapeutics is a preclinical stage gene therapy company developing a proprietary chemogenetics platform for targeted cell therapies that address currently intractable diseases of the nervous system.

Ion channel targets: Proprietary chimeric ion channel
Indication: 0
Website: https://www.redpinrx.com/
Location: New York, USA

Regulonix is an early-stage biotechnology company developing non-opioid therapeutics that relieve chronic pain.

Ion channel targets: Nav1.7
Indication: Chronic pain
Website: https://regulonix.com
Location: Tucson, USA

Rhizen Pharmaceuticals is a clinical-stage oncology-focused specialty company developing differentiated products through cutting-edge science and strategic partnerships.

Ion channel targets: CRAC
Indication: Multiple indications
Website: https://rhizen.com/
Location: Basel, Switzerland

RogCon is a biotechnology company focused on discovering and developing novel therapeutics for children suffering from SCN2A mutations.

Ion channel targets: SCN2A
Indication: Epilepsy, autism
Website: https://www.rogcon.com/
Location: Miami, USA

RogCon U.R., a sister company of RogCon Biosciences, is focused on the research and development of novel, disease-modifying compounds that up-regulate SCN2A for the treatment of loss-of-function mutations in SCN2A causing autism and epilepsy.

Ion channel targets: SCN2A
Indication: Epilepsy, autism
Website: https://www.rogcon.com/company/rogcon-u-r/
Location: Miami, USA

Salipro Biotech is a biotech company focused on unlocking challenging drug targets for the development of next-generation therapeutics.

Ion channel targets: Undisclosed ion channel targets.
Indication: 0
Website: https://www.salipro.com/
Location: Stockholm, Sweden

Saniona is a biopharmaceutical company focused on discovering, developing and delivering innovative treatments for rare disease patients.

Ion channel targets: GABAA alpha3, KCa3.1
Indication: Rare neuropathic disorders, rare inflamatory and fibrotic disorders
Website: https://saniona.com
Location: Glostrup, Denmark

selectION develops highly selective peptide blockers for ion channels.

Ion channel targets: Kv1.3
Indication: Effector memory T cell driven diseases
Website: http://selectiontherapeutics.com
Location: San Diego, USA

Shionogi is a drug-discovery-based pharmaceutical company discovering and developing pharmaceutical products.

Ion channel targets: P2X3
Indication: Neuropathic pain, Sleep Apnea Syndrome, Refractory chronic cough
Website: https://www.shionogi.com/
Location: Osaka, Japan

SiteOne Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of hypersensitivity disorders such as chronic cough, itch and pain.

Ion channel targets: Nav1.7, Nav1.8
Indication: Acute pain, chronic pain, chronic cough, ocular surface pain
Website: https://www.siteonetherapeutics.com
Location: San Francisco, USA

Soleno Therapeutics is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases.

Ion channel targets: KATP
Indication: Prader-Willi Syndrome
Website: https://soleno.life
Location: Redwood City, USA

Soricimed Biopharma is a clinical stage drug development company dedicated to novel trageted treatments for cancer.

Ion channel targets: TRPV6
Indication: Solid tumours
Website: https://www.soricimed.com
Location: Moncton, Canada

Stablix Therapeutics is a biotechnology company pioneering the field of Targeted Protein Stabilization (TPS) to bring transformative medicines to patients with unmet medical need.

Ion channel targets: Undisclosed ion channel targets.
Indication: Rare diseases, cancer and immunological disorders
Website: https://www.stablix.com/
Location: New York, USA

Stoke Therapeutics is pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression.

Ion channel targets: Nav1.1
Indication: Dravet syndrome
Website: https://www.stoketherapeutics.com/
Location: Bedford, USA

Translate Bio, a Sanofi Company, is focused on developing a new class of potentially transformative mRNA medicines.

Ion channel targets: CFTR
Indication: Cystic Fibrosis
Website: https://translate.bio/
Location: Lexington, USA

Vast Bioscience offers the pharmaceutical industry a unique opportunity to develop innovative drugs with superior potency, target selectivity and safety.

Ion channel targets: Nav1.7, Nav1.8
Indication: Pain
Website: http://www.vastbioscience.com/
Location: Toowong, USA

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases.

Ion channel targets: CFTR, Nav1.8
Indication: Cystic Fibrosis, acute pain
Website: https://www.vrtx.com/
Location: Boston, USA

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other CNS disorders.

Ion channel targets: NMDA receptor
Indication: Major depressive disorder, Neuropathic pain, Epilepsy, Suicidal Ideation
Website: https://www.vistagen.com/
Location: San Francisco, USA

Xenon Pharmaceuticals is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders.

Ion channel targets: Kv7, Cav2.1, Cav3, Nav1.6, Nav1.2, Nav1.7
Indication: Adult Focal Epilepsy, Major Depressive Disorder, Orphan Pediatric Epilepsy (KCNQ2-DEE), Pediatric Absence Epilepsy, Rare Pediatric Epilepsy (SCN8A-DEE), Focal-Onset Seizures in Adults, Post-Operative Pain
Website: https://www.xenon-pharma.com
Location: Burnaby, Canada

YourChoice Therapeutics is focused on developing birth control options that are hormone-free, safe, easy to use and effective.

Ion channel targets: CatSper
Indication: Non-hormonal contraception
Website: https://www.yourchoicetx.com/
Location: Berkeley, USA